MedTrace Logo

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

NCT00113880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63061

Last updated 2013-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to expand the data describing the safety profile of FluMist in the indicated populations (5-8, 9-17, and 18-49 years of age) and to assess the safety of annual revaccination in those who received FluMist in 2 or more consecutive years.

Conditions

  • Healthy

Interventions

BIOLOGICAL

FluMist

Nasal Sprayer dose of FluMist with annual follow up

BIOLOGICAL

FluMist

Nasal Sprayer dose of FluMist with annual follow up

BIOLOGICAL

FluMist

Nasal Sprayer dose of FluMist with annual follow up

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Christopher Ambrose, M.D. · MedImmune LLC

Eligibility

Min Age
5 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2008-09-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113880 on ClinicalTrials.gov